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doi:10.1016/j.jtcvs.2007.01.093bjective: Melagatran, the active form of ximelagatran, is a novel, direct thrombin
nhibitor that does not have a narrow therapeutic window regarding hemorrhagic
nd thromboembolic events. We aimed to determine whether melagatran would be
ffective in preventing thrombus formation on heterotopically placed mechanical
eart valves.
ethods: A graft containing a bileaflet mechanical heart valve was implanted in the
escending thoracic aorta of domestic swine. Two groups of 6 animals received
aily subcutaneous injections of either melagatran (2.4 mg/kg, 3 times per day) or
alteparin (175 U/kg, 2 times per day) for 30 days. Four control animals received no
nticoagulation therapy. Fecal HemoQuant and serum hemoglobin levels were
ecorded. Thirty days after the procedure, platelets were labeled with indium 111,
he abdominal organs were inspected, and thrombi and platelets deposited on the
alve were measured.
esults: Median thrombus burden on the valves was 0.4 mg (interquartile range,
.15-5.45 mg) with melagatran, 0.5 mg (interquartile range, 0-14.5 mg) with
alteparin, and 168 mg (interquartile range, 32.5-665.75 mg) for controls (melagat-
an vs dalteparin and control; P .04). Median platelet deposition on the valves was
(interquartile range, 0-8.9 104) with melagatran, 49.9 104 (interquartile range,
7.9  104-191.8  104) with dalteparin, and 115.2  104 (interquartile range,
.6  104-243  104) for controls (melagatran vs dalteparin and control;
 .02). Melagatran did not increase the risk of thromboembolism or bleeding.
onclusions: Thrombus and platelet accumulation on the prosthetic valves was
ecreased by melagatran and dalteparin. The use of melagatran or other related
irect thrombin inhibitors warrants further study in prophylaxis of thromboembo-
ism in patients with mechanical heart valves.
or more than 45 years, vitamin K antagonists such as warfarin have been used
to prevent thromboembolic complications in patients with mechanical heart
valve prostheses. Low-molecular-weight heparins (LMWH) have also been
sed for thromboembolism prophylaxis, generally for short-term therapy. The oral
nd subcutaneous anticoagulants used at present have several limitations that make
heir use in the outpatient setting cumbersome. For example, routine invasive
onitoring is required to maintain therapeutic levels of warfarin owing to its narrow
herapeutic range. Further, warfarin has a slow onset of action and has the potential
or numerous interactions with other medications and foods. Invasive monitoring is
lso required for unfractionated heparin, and an injection is needed for prophylaxis
ith LMWH.
Ximelagatran, the oral prodrug of melagatran, is the first orally administered
irect thrombin inhibitor to reach phase III clinical trials. It has several advantages
ver the currently approved anticoagulants, including its availability in both paren-
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CSPeral and oral formulations, prompt onset of action, predict-
ble dose response (no coagulation monitoring necessary),
irtually no interaction with food, and a low potential for
nteraction with other medications.1 Ximelagatran has been
valuated for several potential indications, including for the
reatment2 and prevention3,4 of venous thromboembolism,
or the prevention of cardioembolic events in patients with
onvalvular atrial fibrillation,5 and for decreasing mortality
n patients who have had a recent myocardial infarction.6
owever, no data exist in the literature regarding the effec-
iveness of either ximelagatran or melagatran in preventing
hrombotic complications from mechanical heart valve
rostheses. We aimed to determine whether melagatran is
ffective in preventing thrombus formation on heterotopi-
ally placed mechanical heart valves.
aterials and Methods
nesthesia and Surgical Preparation
eterotopic, valved conduit implantation was performed in 16 do-
estic swine (weight, 35-45 kg). Each animal was randomly assigned
o receive 1 of 3 anticoagulation options: 6 received melagatran
AstraZeneca R&D, Mölndal, Sweden), 6 received dalteparin sodium
Pfizer, New York, NY), and 4 animals received no anticoagulation
herapy. The study protocol was approved by the Mayo Foundation
nstitutional Animal Care and Use Committee, and the animals re-
eived humane care in compliance with the “Guide for the Care and
se of Laboratory Animals” (NIH Publication No. 85-23).
perative Procedure
9.6F single-lumen cuffed Hickman catheter (Bard Access Sys-
ems, Salt Lake City, Utah) was placed into the left external
ugular vein and tunneled subcutaneously to exit the skin between
he scapulas. Proper location was confirmed fluoroscopically.
The valved conduit was constructed from a 19-mm SJM Mas-
ers Series aortic valved graft (St Jude Medical, Inc, Minneapolis,
inn). A left thoracotomy in the fifth intercostal space was per-
ormed, and the descending aorta was exposed. The animal was
eparinized (300 U/kg), and a side-biting clamp was placed onto
he distal thoracic aorta (Figure 1). Maintenance of a blood pres-
ure reading from the femoral arterial line ensured distal flow
hrough the aorta. The aorta was incised and the efferent limb of
he graft anastomosed to the distal thoracic aorta with a running
-0 polypropylene suture. This procedure was repeated for the
roximal aorta and afferent limb of the graft. The graft was deaired
y filling it with blood before the final suture was tied in place. The
ypassed portion of the native aorta was then ligated with 2
mbilical tapes. Anticoagulation was reversed with protamine
Abbreviations and Acronyms
aPTT  activated partial thromboplastin time
Hb  hemoglobin
IQR  interquartile range
LMWH low-molecular-weight heparin0.5-1 mg/100 U heparin), and a 28F chest tube was inserted. The t
60 The Journal of Thoracic and Cardiovascular Surgery ● Auguhest was then closed in layers. After the animal was extubated,
uoroscopy of the valve was obtained to ascertain leaflet motion.
nticoagulation Protocol
arget levels of anticoagulation were set in accordance with hu-
an standards: specifically, a prolongation of the activated partial
hromboplastin time (aPTT) to 1.5 to 2 times baseline for the direct
hrombin inhibitor (melagatran) group7 and an elevation of the
nti-Xa activity level (with the factor Xa inhibition test) to 0.6 to
.0 IU/mL for the LMWH (dalteparin) group.8 Anticoagulant
dministration was begun the morning of the first postoperative
ay and continued for 30 days. The melagatran group (n  6)
eceived 2.4 mg/kg melagatran subcutaneously every 8 hours; the
MWH group (n  6) received dalteparin at 175 U/kg subcuta-
eously every 12 hours. The control group (n  4) did not receive
nticoagulation.
ong-Term Care
ll animals were followed up at our in-house animal care facility
or the 30-day duration of the study, where they were monitored
aily by the investigators and a veterinary technician. The animals
ere weighed every 3 days to maintain the appropriate weight-
ased dose of anticoagulation therapy. Stool HemoQuant and
erum hemoglobin (Hb) levels were determined weekly. A Hemo-
uant level less than 2 mg Hb per gram stool was considered
ormal9 and was also compared with the HemoQuant levels of 12
igs that had not received any anticoagulation or operative
ntervention.
The aPTT and anti-Xa activity levels were determined by serial
lood draws performed on postoperative days 4, 15, and 29. The
lood was sampled immediately before anticoagulant administra-
igure 1. Cartoon depicting the heterotopic model. A valved graft
as been implanted onto the aorta, with diversion of the blood-
tream through the conduit by ligation of the aorta. (Used with
ermission of Mayo Foundation for Medical Education and
esearch.)ion and then 0.5, 1, 2, and 4 hours after administration. All
st 2007
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Paboratory studies were performed in the standard manner of the
ayo Medical Laboratories (Mayo Clinic, Rochester, Minn).
So that platelet deposition on the valves could be quantified,
nimals underwent autologous platelet labeling with indium 111.10
fter the labeling, the animals were anesthetized, placed on me-
hanical ventilation, and treated with heparin. A complete blood
ount was obtained. The mechanical valve was explanted and the
onduit was removed from the valve. The valve was placed into a
cintillation counter, and the level of radioactivity was recorded.
ackground level of radioactivity was also recorded, as was the
mount of radioactivity emanating from 2 10-mL tubes of blood
btained at the time the animals were put to death. The average
mount of radioactivity from one platelet could be determined with
he knowledge of the platelet count (platelet radioactivity  blood
adioactivity/[blood volume  platelet count]). The number of
latelets deposited  valve radioactivity/platelet radioactivity. Fi-
ally, any thrombus on the valve was removed and weighed.
A laparotomy was performed, and the liver, spleen, and large
nd small bowel were inspected grossly for evidence of thrombo-
mbolic or bleeding events. Both kidneys were inspected grossly,
xplanted, and then examined microscopically for evidence of
hromboembolism.
tatistical Analysis
ll analyses were conducted with SAS version 8.2 (SAS Institute,
nc, Cary, NC). Continuous data are expressed as mean  SEM.
eans of 2 groups were compared with the rank sum test. Means
f multiple groups were compared with the Kruskal–Wallis test.
esults
he coagulation profiles showed that clinically relevant
evels of anticoagulation were achieved in both experimen-
al groups. On the fourth postoperative day, the mean base-
ine aPTT of the animals that received melagatran was 79
4 seconds and doubled to 159  29 seconds 15 minutes
fter administration. The aPTT remained elevated through
0 minutes at 139  28 seconds and decreased to 45  11
econds by 2 hours. The mean baseline anti-Xa activity
evel on the fourth postoperative day for the animals that
eceived dalteparin was 0.08  0.01 IU/mL and rose to
.63  0.12 IU/mL at 1 hour. The elevation was prolonged
ast 4 hours (0.36  0.04 IU/mL). More pronounced anti-
oagulation response was obtained the longer the animals
eceived anticoagulation.
Differences in thrombus deposition were evident on
ross inspection of the explanted valves (Figure 2). This
ifference was confirmed by measuring the weight of the
hrombus and the number of platelets deposited onto the
alves. Median thrombus burden on the valves was 0.4 mg
interquartile range [IQR], 0.15-5.45 mg) for the melagatran
roup, 0.5 mg (IQR, 0-14.5 mg) for the dalteparin group,
nd 168 mg (IQR, 32.5-665.75 mg) for the control group
Figure 3). The overall difference in the thrombus weights
mong the 3 groups did not reach significance (P  .08). A
tatistically significant difference was found when the mel- b
The Journal of Thoracicgatran group was compared with the dalteparin and control
roups combined (P  .04).
The median number of platelets deposited on the valves
as 0 (IQR, 0-8.9  104) for the melagatran group, 49.9 
04 (IQR, 27.9 104-191.8 104) for the dalteparin group,
nd 115.2  104 (IQR, 9.6  104-243  104) for the
ontrols (melagatran group vs dalteparin or control group;
 .02).
Melagatran did not increase the risk of bleeding events
ompared with dalteparin. The mean fecal Hb level was
.58  0.23 mg Hb per gram stool for the melagatran
roup, 0.57  0.12 mg Hb per gram stool for the dalte-
arin group, and 0.62  0.17 mg Hb per gram stool for
he control group (P  .70). On postoperative day 1, the
ean serum Hb of the dalteparin group was 9  0.9 g/dL,
hich was lower than that of the melagatran group (10.8 
.3 g/dL). By day 29 of the study, the serum Hb levels were
lmost equal: melagatran group 11.8  0.5 g/dL and dalte-
arin group 12.2  0.6 g/dL (P  .70).
At necropsy, neither gross inspection of the abdominal
rgans nor microscopic examination of the kidneys demon-
trated evidence of thromboembolism in any of the groups.
iscussion
o our knowledge, this is the first report of a direct thrombin
nhibitor being used for thromboprophylaxis for mechanical
eart valves. We hypothesized that melagatran could be
sed for thromboembolism prophylaxis for mechanical
eart valve prostheses. Data exist supporting the long-term
se of LMWH in patients with mechanical heart valves.11
e chose not to use warfarin because previous attempts to
se it in a porcine model have not been successful. Specif-
cally, Grehan and associatees12 observed a prohibitively
igh number of early deaths when using warfarin in pigs.
The pharmacokinetic properties of melagatran have been
hown to be stable and reproducible, which supports fixed-
ose administration without routine coagulation monitoring.
pecific circumstances (eg, emergencies, research) may
rise, however, in which the clinician may want to deter-
ine the anticoagulation effect of melagatran and will need
o know which coagulation assay to order. By inhibiting the
hrombin-mediated conversion of fibrinogen to fibrin (one
f the last steps of the final common pathway of the coag-
lation cascade), melagatran affects all of the coagulation
ssays.1 Although the aPTT is relatively insensitive to
elagatran concentration, it does provide a qualitative in-
ication of the anticoagulation effect. Furthermore, prolon-
ation of the aPTT is consistent over a wide range of patient
emographics and disease states and when taken with other
rugs and food.
The thrombin time assay is very sensitive to melagatran
oncentrations, but defining a “normal” thrombin time may
e difficult and requires the establishment of standard
and Cardiovascular Surgery ● Volume 134, Number 2 361
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CSPurves locally. In general, there is limited experience with
sing the activated clotting time in clinical trials, and the
rothrombin time/international normalized ratio gives un-
redictable results. Although other tests (ecarin clotting
ime, prothrombinase-induced clotting time) may be of
Figure 2. Photographs illustrating thrombus accumula
animals receiving melagatran (A), dalteparin (B), or no
both melagatran and dalteparin decrease thrombus foalue in determining the extent of anticoagulant effect, they l
62 The Journal of Thoracic and Cardiovascular Surgery ● Auguo not have the wide clinical availability of either the aPTT
r the thrombin time assays.
In the present study, thrombus accumulation on the pros-
hetic valves was reduced by melagatran and dalteparin, which
as confirmed visually and by thrombus weight. Fewer plate-
n the explanted valves 30 days after implantation in
coagulation therapy (C). Visual inspection shows that
on.tion o
anti
rmatiets were deposited on the valves of the melagatran group,
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Phich may be explained by the platelet-inhibiting action of this
irect thrombin inhibitor. Melagatran did not increase risk of
istal thromboembolism or bleeding compared with dalteparin,
hich mirrors the results of recent large clinical trials.13,14
The porcine model is particularly well suited for study-
ng novel anticoagulants. The fibrinolytic mechanisms15 and
latelet function16 of humans are more similar to swine than
hey are to sheep, and swine have been used in preclinical
tudies evaluating the thrombogenicity of coronary artery
tents and vascular prostheses.17,18 Although the sheep
odel has been used for determining the performance char-
cteristics of valvular prostheses,19 it did not predict the
hrombotic potential of the Medtronic Parallel valve
Medtronic, Inc, Minneapolis, Minn).20 For these reasons,
he thromboembolism prophylaxis capacity of novel antico-
gulants probably should not be tested in the ovine model.
We believe that a heterotopically placed mechanical
Figure 2alve is an appropriate model for screening the thrombo- h
The Journal of Thoracicmbolic prophylaxis potential of novel anticoagulants. The
se of a heterotopic model eliminates many of the technical
omplications and expenses associated with cardiopulmo-
ary bypass. Also, the substantial somatic growth of pigs
1-2 kg/d) raises the concern of perivalvular leaks and
rosthesis–to–animal size mismatch, which is obviated by a
eterotopic model. The use of Yucatan minipigs has been
dvocated as a means to avoid the somatic growth issue21
ut has not been extensively used because of the high cost
f this strain.
The heterotopic model we used subjects the valve to the
ontinuous forward stream of blood in the descending aorta,
ausing the leaflets to remain in the open position. Postop-
rative fluoroscopy demonstrated that the valve leaflets re-
ained continuously in the open position. It has been hy-
othesized that high-leak jet velocities at the time of valve
losure create a “door-slamming” effect that may keep the
tinued. Coninge regions free of deposited blood elements.22 Lacking
and Cardiovascular Surgery ● Volume 134, Number 2 363
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CSPhe thrombus-clearing mechanisms of moving leaflets, a
echanical valve heterotopically placed may be at in-
reased risk for thrombus formation compared with an
rthotopically placed valve.
The US Food and Drug Administration has not approved
imelagatran for use in humans.23 Transient elevated levels
f alanine aminotransferase during long-term administration
emain the principal source of concern regarding its usage.24
imelagatran (Exanta; AstraZeneca) was approved by the
uropean regulatory authorities in May 2004 for short-term
se in patients undergoing hip- or knee-replacement sur-
ery,25 but it has subsequently been voluntarily withdrawn
y its manufacturer for ongoing concerns of liver toxicity.26
lthough ximelagatran is the first of its class to reach phase
II clinical trials, novel direct thrombin inhibitors are al-
eady being developed.27
This study was limited in duration and in the number of
nimals. Future studies should address these limitations, in
ddition to developing a model for orthotopic valve implan-
ation and searching for a porcine model of stable antico-
gulation with warfarin.
In conclusion, as novel anticoagulants are being devel-
ped, a model in which to evaluate their thromboembolic
rophylaxis efficacy must be developed. We used a hetero-
opically placed valved conduit in a porcine model to eval-
ate the direct thrombin inhibitor melagatran, which we
ompared with dalteparin and no anticoagulation. We dem-
nstrated that melagatran is equivalent to dalteparin in pre-
enting thrombus formation on mechanical heart valves and
hat it does not increase the risk for thromboembolic or
leeding events. This study showed that a heterotopic model
f mechanical heart valve implantation is technically
chievable and sufficiently demanding to screen the throm-
igure 3. Box plots showing median (interquartile range) throm-
us weight for the melagatran, dalteparin, and control groups.
Melagatran vs dalteparin and control, P  .04.)oembolism prophylaxis efficacy of novel anticoagulants.
64 The Journal of Thoracic and Cardiovascular Surgery ● Augun the future, direct thrombin inhibitors may have an im-
ortant role in thromboprophylaxis for patients with me-
hanical valves.
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